Peptide Report
Source-backed explainers, regulatory tracking, and research notes for readers trying to make sense of the peptide conversation.
BPC-157
Regulatory Watch
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry record has no posted efficacy result, and a small uncontrolled knee-pain report does not establish benefit. It is not FDA-approved and is prohibited in sport.
Popular YouTube shows can flag what readers are hearing. We track them as media signals, then verify claims against primary sources before updating guides.
GHK-Cu and injectable peptides
A board-certified dermatologist separates topical copper-peptide evidence from the newer injectable GHK-Cu trend using a clear, product-specific visual explainer.
82K views · 536 comments · 2.7M subscribers · checked Jul 10, 2026
Topical GHK-Cu has a longer cosmetic research record than injectable GHK-Cu. Human evidence for injectable use remains limited.
BPC-157 evidence
Two physicians use a literal BPC-157 vial and an evidence-versus-hype frame to address the compound readers most often associate with injury recovery.
169K views · 919 comments · 1.3M subscribers · checked Jul 10, 2026
The physicians explain why animal findings and online enthusiasm do not establish proven human benefits. Controlled human evidence remains limited.
Peptide safety
A high-production interview built around unknown risks gives the video rail a broader safety lens beyond single-compound benefit claims.
8.5K views · 88 comments · 140K subscribers · checked Jul 10, 2026
The strongest part is its focus on unanswered safety questions. Long-term human safety evidence for BPC-157 and TB-500 remains limited.
Retatrutide and online sales
A concise news report connects the nickname 'reta' to the real investigational drug and the safety questions around online availability.
7.2K views · 30 comments · 559K subscribers · checked Jul 10, 2026
Retatrutide is still investigational. Claims about online availability, legal status, and enforcement should be checked against current FDA records.
Starting points for source-backed peptide research. These are editorial guide queues, not purchasing recommendations.
A ranked starting point for the pages most likely to need regulatory or source updates.
See guideThe peptide guides currently anchored by FDA advisory and risk-source records.
See guidePlain-English explainers that separate online claims from reviewed sources.
See guideHow the site keeps claims, citations, analytics, and review dates in one loop.
See guide
5-Amino-1MQ
Regulatory Watch
5-Amino-1MQ is a small-molecule NNMT inhibitor with published efficacy findings limited to cell and rodent studies. No exact-name ClinicalTrials.gov record was located at the August 1, 2026 research cutoff, and this review did not establish human benefits, safety, pharmacokinetics, or a clinical formulation. FDA has specifically identified 5-Amino-1MQ as ineligible for 503B bulk-compounding exemptions.
AOD-9604
Regulatory Watch
AOD-9604 is a synthetic fragment of human growth hormone developed as a weight-loss candidate. Its Phase 2 obesity program did not meet the primary weight-loss endpoint, development was discontinued, and the compound is not FDA-approved or TGA-approved for any indication.
Argireline (acetyl hexapeptide-8)
Evidence Guide
Small studies have reported modest wrinkle changes with some Argireline formulations, but results are inconsistent and ordinary topical formulations show very low penetration beyond the outer skin. It is not equivalent to botulinum toxin.
Cerebrolysin
Regulatory Watch
Cerebrolysin is a porcine brain-derived peptide preparation used for neurological indications in several countries. It is not FDA-approved in the United States. Clinical studies and systematic reviews report mixed findings, with continued calls for larger and higher-quality trials.
Browse the current peptide explainers by topic, status, and review depth.
5-Amino-1MQ
Regulatory Watch
5-Amino-1MQ is a small-molecule NNMT inhibitor with published efficacy findings limited to cell and rodent studies. No exact-name ClinicalTrials.gov record was located at the August 1, 2026 research cutoff, and this review did not establish human benefits, safety, pharmacokinetics, or a clinical formulation. FDA has specifically identified 5-Amino-1MQ as ineligible for 503B bulk-compounding exemptions.
AOD-9604
Regulatory Watch
AOD-9604 is a synthetic fragment of human growth hormone developed as a weight-loss candidate. Its Phase 2 obesity program did not meet the primary weight-loss endpoint, development was discontinued, and the compound is not FDA-approved or TGA-approved for any indication.
Argireline (acetyl hexapeptide-8)
Evidence Guide
Small studies have reported modest wrinkle changes with some Argireline formulations, but results are inconsistent and ordinary topical formulations show very low penetration beyond the outer skin. It is not equivalent to botulinum toxin.
Cerebrolysin
Regulatory Watch
Cerebrolysin is a porcine brain-derived peptide preparation used for neurological indications in several countries. It is not FDA-approved in the United States. Clinical studies and systematic reviews report mixed findings, with continued calls for larger and higher-quality trials.
CJC-1295 (no DAC)
Evidence Guide
CJC-1295 without DAC (Mod GRF 1-29) is a tetrasubstituted GHRH 1-29 analog with a half-life of approximately 30 minutes. Unlike the DAC form, it does not bind albumin and is cleared rapidly. It is the standard form combined with ipamorelin in research-chemical and telehealth channels. It is not FDA-approved for any indication, and no standalone clinical trial has evaluated it.
CJC-1295 (with DAC)
Evidence Guide
CJC-1295 with DAC is a synthetic GHRH analog developed by ConjuChem using drug affinity complex (DAC) technology to bind albumin and extend half-life to 6-8 days. It is not FDA-approved; ConjuChem discontinued clinical development. A separate profile covers CJC-1295 without DAC (Mod GRF 1-29), the short-acting form commonly stacked with ipamorelin.
Latest Guides
| Topic | Status | Claims | Sources | Next review |
|---|---|---|---|---|
| 5-Amino-1MQ | Regulatory watch | 9 | 7 | 2026-09-01 |
| AOD-9604 | Regulatory watch | 3 | 3 | 2026-07-29 |
| Argireline (acetyl hexapeptide-8) | Evidence review | 8 | 8 | 2026-08-12 |
| BPC-157 | Regulatory watch | 3 | 12 | 2026-07-24 |
| Cerebrolysin | Regulatory watch | 3 | 4 | 2026-07-29 |
| CJC-1295 (no DAC) | Evidence review | 2 | 3 | 2026-09-05 |
| CJC-1295 (with DAC) | Evidence review | 3 | 3 | 2026-09-05 |
| Dihexa | Research watch: preclinical only | 3 | 5 | 2026-07-29 |
| DSIP | Regulatory watch | 3 | 4 | 2026-07-24 |
| Epitalon | Regulatory watch | 3 | 4 | 2026-07-24 |
| Fisetin | Evidence review | 3 | 3 | 2026-07-29 |
| GHK-Cu | Evidence review | 4 | 6 | 2026-08-13 |
| Ipamorelin | Evidence review | 3 | 3 | 2026-07-29 |
| KPV | Regulatory watch | 3 | 3 | 2026-07-24 |
| LL-37 | Regulatory watch | 3 | 4 | 2026-07-29 |
| Matrixyl (Palmitoyl Pentapeptide-4) | Evidence review | 3 | 4 | 2026-07-29 |
| Metformin | Evidence review | 4 | 6 | 2026-07-29 |
| Methylene Blue | Regulatory watch | 3 | 4 | 2026-07-29 |
| MK-677 (Ibutamoren) | Evidence review | 3 | 4 | 2026-07-29 |
| MOTS-c | Regulatory watch | 3 | 4 | 2026-07-24 |
| NAD+ / NMN / NR | Regulatory watch | 4 | 8 | 2026-07-29 |
| Noopept | Research watch: registered in Russia, sold as supplement in US | 3 | 5 | 2026-07-29 |
| Rapamycin (sirolimus) | Evidence review | 6 | 8 | 2026-08-12 |
| Retatrutide | Regulatory watch | 10 | 11 | 2026-08-12 |
| Selank | Research watch: preclinical and limited Russian clinical use | 3 | 3 | 2026-07-29 |
| Semaglutide | Evidence review | 4 | 11 | 2026-07-29 |
| Semax | Regulatory watch | 3 | 3 | 2026-07-24 |
| Sermorelin | Evidence review | 3 | 3 | 2026-07-29 |
| Spermidine | Evidence review | 3 | 5 | 2026-07-29 |
| TB-500 | Regulatory watch | 2 | 2 | 2026-07-24 |
| Tesamorelin | Regulatory watch | 3 | 4 | 2026-07-29 |
| Thymosin Alpha-1 | Regulatory watch | 3 | 3 | 2026-07-29 |
| Tirzepatide | Evidence review | 4 | 9 | 2026-07-29 |